Cancer NetworkOriginal article
<![CDATA[Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence]]>
ConferenceCAR T-Cell TherapyBispecific AntibodiesPositive
AI Analysis
Summary
Dr. Ralph V. Boccia discussed the potential clinical benefits of using CAR T-cell therapy followed by bispecific antibodies as the preferred treatment sequence at first relapse in multiple myeloma patients.
Importance:3/10
Sentiment:
0.30
CAR T-cell therapyBispecific antibodiesMultiple myelomaTreatment sequencingOncology
Related Companies
Read the original article
Published by Cancer Network on October 12, 2026 6:00 PM